Abstract. There is increasing evidence that microRNAs (miRs) are implicated in tumor development and progression; however, their specific roles in osteosarcoma are not well understood. The aim of the present study was to investigate the role of miR-506 in the pathogenesis of osteosarcoma. The expression levels of miR-506 and astrocyte elevated gene-1 (AEG-1) mRNA were detected using quantitative polymerase chain reaction, and the protein levels of AEG-1, β-catenin, c-myc and cyclin D1 were determined using western blot analysis. The effects of miR-506 and AEG-1 on cell viability, colony forming ability and apoptosis were assessed using MTT assay, colony formation assay, and flow cytometry, respectively. Lucifer reporter assays were used to demonstrate whether AEG-1 is a direct target of miR-506. The present study identified that miR-506 was downregulated in osteosarcoma tissues and cells. Overexpression of miR-506 suppressed the proliferation and induced apoptosis in osteosarcoma cells in vitro and inhibited tumor formation in vivo. Overexpression of miR-506 significantly inhibited the luciferase activity of AEG-1 with a wild-type 3'-untranslated region, providing clear evidence that AEG-1 was a direct and functional downstream target of miR-506. Similar to the overexpression of miR-506, downregulation of AEG-1 lead to an inhibitory effect on osteosarcoma in vitro. Furthermore, overexpression of miR-506 or downregulation of AEG-1 inhibited the Wnt/β-catenin signaling pathway, and inhibition of this pathway by β-catenin small interfering RNA or CGP049090, a small molecule inhibitor, suppressed cell proliferation and induced apoptosis in vitro. Overall, the present data indicated that miR-506 functions as a tumor suppressor by targeting AEG-1 in osteosarcoma via the regulation of the Wnt/β-catenin signaling pathway.
Introduction
Osteosarcoma is the most common primary bone malignancy in children and adolescents, and is characterized by a highly malignant tendency to destroy the surrounding tissues and metastasize almost exclusively to the lung, which is the primary cause of mortality among patients (1, 2) . In young patients, osteosarcoma is most often localized in the distal femur and proximal tibia region (3) . Although osteosarcoma has been treated with neoadjuvant chemotherapy in combination with surgery for more than three decades, patients with recurrent or metastatic osteosarcoma have an extremely poor prognosis, with a long-term survival rate of <10% (4) . To date, the molecular mechanisms underlying the initiation, development and metastasis of osteosarcoma are not fully elucidated, and it is essential to identify novel therapeutic targets and develop therapeutic strategies against osteosarcoma.
MicroRNAs (miRs) belong to a group of small noncoding, single-stranded RNA fragments measuring 18-25 nucleotides in length, which are critical regulators in tumorigenesis and cancer progression (5) . Previously, miRs have been demonstrated to suppress translation or directly cleave target mRNA through complementary sequence pairing to the 3'-untranslated region (UTR) or coding region of target mRNA (6) . These data indicate that miRs may be used as diagnostic biomarkers and may function either as oncogenes or tumor suppressors based on the effects of their target mRNAs (7, 8) . It has been reported in osteosarcoma that multiple miRs, including miR-29, miR-125b, miR-143 and miR-199a-3p, are involved in tumor growth, progression and metastasis (9) (10) (11) (12) . A previous study revealed that restoration of miR-506 in malignant transformed human bronchial epithelial cells suppressed cell proliferation (13) . In addition, overexpression of miR-506 inhibited transforming growth factor-β-induced epithelial-mesenchymal transition and suppressed the adhesion, invasion and migration of human breast cancer cells (14 (15) . Although miR-506 has been subjected to extensive study in recent years, its role in the initiation and progression of osteosarcoma, and the molecular mechanisms by which miR-506 exerts its effects, are poorly understood. Astrocyte elevated gene-1 (AEG-1), also known as lysine-rich carcinoembryonic antigen-related cell adhesion molecule 1 or metadherin, was initially characterized as a human immunodeficiency virus-1-and tumor necrosis factor-α-inducible gene in primary human fetal astrocytes (16, 17) . Although AEG-1 is ubiquitously expressed in numerous cell types, the expression level of AEG-1 is higher in certain solid tumors, including breast and prostate cancer, malignant glioma, hepatocellular carcinoma and melanoma, compared to normal counterpart tissues (18) . In addition, patients with elevated AEG-1 levels have shorter overall survival times compared with patients with lower AEG-1 levels (19) . Previously, certain studies have demonstrated that AEG-1 is significantly associated with chemoresistance and progression of osteosarcoma, and AEG-1 has been suggested to act as a useful biomarker for the prediction of osteosarcoma progression and prognosis (20) (21) (22) . Therefore, targeted downregulation of AEG-1 may be an effective treatment strategy against osteosarcoma.
The aim of the present study was to investigate the role of miR-506 in the pathogenesis of osteosarcoma. The present results revealed that the expression of AEG-1 was significantly increased, while the level of miR-506 was significantly decreased, in human osteosarcoma tissues and cells. Overexpression of miR-506 and knockdown of AEG-1 attenuated proliferation and promoted apoptosis of osteosarcoma in vitro. Furthermore, miR-506 overexpression was demonstrated to inhibit osteosarcoma cell growth in vivo. Therefore, the present study provides evidence that miR-506 suppresses osteosarcoma development by targeting AEG-1, partly via regulating the Wnt/β-catenin signaling pathway.
Materials and methods
Clinical specimens and cell culture. A total of 19 pairs of primary osteosarcoma tissues and matched adjacent non-cancerous bone tissues were obtained from the First Affiliated Hospital of Zhengzhou University (Zhengzhou, China) to identify the expression level of miR-506 using quantitative polymerase chain reaction (qPCR). The characteristics of the patients are listed in Table I . All diagnoses were determined according to the criteria of the World Health Organization (23 qPCR. Total RNA was extracted from frozen tissues and osteosarcoma cells using TRIzol Reagent (Invitrogen™), according to the manufacturer's protocol. In total, 1 µl DNase (Qiagen, Inc., Valencia, CA, USA) was used. The reverse transcriptase of RNA was performed with the miScript II RT kit (Qiagen, Inc.), according to the manufacturer's protocol. The expression level of miR-506 was quantified by qPCR using TaqMan microRNA Assays (Applied Biosystems™; Thermo Fisher Scientific, Inc.). Specific primer sets were designed using Primer Premier version 5.0 software (PREMIER Biosoft, Palo Alto, CA, USA) and synthesized by Sangon Biotech Co., Ltd. (Shanghai, China) as follows: miR-506, forward 5'-GAC ATG CAT AAG GCA CCC TTC-3' and reverse 5'-GTG CAG GGT CCG AGGT-3'; AEG-1, forward 5'-AAA TAG CCA GCC TAT CAA GAC TC-3' and reverse 5'-TTC AGA CTT GGT CTG TGA AGG AG-3'; β-catenin, forward 5'-GCT GAT TTG ATG GAG TTG GA-3' and reverse 5'-TCA GCT ACT TGT TCT TGA GTG AA-3'; and β-actin, forward 5'-TGG ACT TCG AGC AGG AAA TGG-3' and reverse 5'-ACG TCG CAC T TC ATG ATC GAG-3'. qPCR was performed on a ABI 7900 Sequence Detection System (Applied Biosystems; Thermo Fisher Scientific, Inc.) using the following cycling conditions: Denaturation, 95˚C for 15 min, followed by 40 cycles of 94˚C for 15 sec, 55˚C for 30 sec and 72˚C for 30 sec. The relative expression of mRNA was calculated and normalized using the ∆Cq method (24) relative to β-actin. Each test was performed in triplicate.
Transfection. Control miR (miR-control; 5'-UGU GCG ACG CGG CUG GAU GCG-3'), hsa-miR-506 mimic (miR-506 mimic; 5'-UAA GGC ACC CUU CUG AGU AGA-3'), control anti-miR (anti-miR-control; 5'-CAC UAC GCA GAA CCG GAA UAU-3'), anti-miR-506 mimic (5'-UCU ACU CAG AAG GGU GCC UUA-3') and small interfering RNA (si) targeting AEG-1 Tumor-node-metastasis stages I + II 7 III + IV 12
coding sequences (si-AEG-1; forward, 5'-GAC ACU GGA GAU GCU AAU AUU-3' and reverse 5'-UAU UAG CAU CUC CAG UGU CUU-3') were chemically synthesized by Genepharma, Co., Ltd. (Shanghai, China). Cells (5x10 5 cells/well) were transfected with the miRs and si using Lipofectamine ® 2000 (Invitrogen™), according to the manufacturer's protocol.
Western blot analysis. Cells were lysed using RIPA Lysis and Extraction Buffer (Thermo Fisher Scientific, Inc.), and protein concentration was measured using BCA Protein Assay kit (Pierce™; Thermo Fisher Scientific, Inc.). Western blot analysis was conducted as described previously (1) . Briefly, following a 48 h transfection, the proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and subsequently transferred to nitrocellulose membranes (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The membranes were blocked with 10% skimmed milk (Sigma-Aldrich, St. Louis, MO, USA) at room temperature for 2 h and incubated overnight at 4˚C with rabbit polyclonal anti-AEG-1 (catalog no., 40-6500; 1:500; Invitrogen™), mouse monoclonal anti-β-catenin (catalog no., 610154; 1:500; BD Transduction Laboratories™; BD Biosciences, Franklin Lakes, NJ, USA), rabbit polyclonal anti-c-myc (catalog no., sc-764; 1:200; Santa Cruz Biotechnology, Inc., Dallas, TX, USA), mouse monoclonal anti-cyclin D1 (catalog no., sc-450; 1:100; Santa Cruz Biotechnology, Inc.), and rabbit polyclonal anti-β-actin (catalog no., 4967; 1:2,000; Cell Signaling Technology, Inc., Danvers, MA, USA) antibodies. After washing, the membranes were incubated for 2 h at room temperature with horseradish peroxidase-conjugated secondary immunoglobulin G goat anti-mouse (catalog no, sc-2005; 1:10,000) or goat anti-rabbit (catalog no, sc-2004; 1:10,000) antibodies (Santa Cruz Biotechnology, Inc.). The proteins were visualized using ImageQuant LAS4000 (GE Healthcare Life Sciences, Chalfont, UK).
MTT assay. For cell viability assays, MG63 cells were transfected with miR-506 mimic or si-AEG-1. Following transfection for 48 h, MG63 cells were seeded in a 96-well plate at a density of 4x10 3 cells per well. After incubation for 24, 48, 72 and 96 h at 37˚C in a humidified atmosphere containing 5% CO 2 , 10 µl MTT [5 mg/ml in phosphate-buffered saline (PBS); Sigma-Aldrich] was added to each well and the plates were incubated for a further 4 h. After removal of the medium, each cell was treated with 150 µl dimethyl sulfoxide to dissolve the formazan crystals. Optical density values were determined using a microplate reader (Model 680 Microplate Reader; Bio-Rad Laboratories, Inc.) at a wavelength of 490 nm.
MG63 cells transfected with si-β-catenin (sense, 5'-CAG UUG UGG UUA AGC UCU UdT dT-3' and antisense, 3'-dT dT GUC AAC ACC AAU UCG AGA A-5'; Genepharma, Co., Ltd) or treated with 0, 5 and 10 µM CGP049090 (Sigma-Aldrich) were seeded in a 96-well plate and incubated for 48 h at 37˚C in a humidified atmosphere containing 5% CO 2 . The subsequent MTT was as aforementioned.
Colony formation assay. Subsequent to transfection for 48 h, MG63 cells were seeded in a 6-well plate at a density of 500 cells per well and cultured for 10 days. Colony formation was viewed by staining the cells with 2% Giemsa solution (Merck Millipore, Darmstadt, Germany) for 10 min following fixation with 10% methanol for 5 min.
Flow cytometry. Cell apoptosis was evaluated using Annexin V/fluorescein isothiocyanate (FITC) Apoptosis Detection kit (BD Biosciences) and propidum iodide (PI; Sigma-Aldrich), according to the manufacturer's protocol. Briefly, cells were harvested using 0.25% trypsin 48 h after transfection or treatment with CGP049090, washed twice with cold PBS, and re-suspended in binding buffer. Subsequently, cells were incubated with 5 µl Annexin V/FITC and 5 µl PI for 15 min at room temperature in the dark. A flow cytometer (BD Biosciences) was used to detect apoptosis in MG63 cells.
Luciferase reporter assays. MG63 cells were seeded in 24-well plates 24 h prior to transfection. Subsequently, the cells were transiently co-transfected with 0.3 µg wild type or mutant reporter plasmid (Agilent Technologies, Santa Clara, CA, USA) and 50 nM miR-506 mimic or miR-control using Lipofectamine 2000. Firefly and Renilla luciferase activities were measured 48 h subsequent to transfection using the Dual Luciferase Assay (Promega, Madison, WI, USA), according to the manufacturer's protocol. Firefly luciferase activity was normalized to Renilla, and the value of firefly luciferase activity/Renilla luciferase activity was analyzed. Three independent experiments were performed in triplicate.
Tumor formation in nude mice. A total of 8, 4-6-week-old, male BALB/c nude mice (nu/nu; 20-25 g) were obtained from Vital River Laboratories Co., Ltd. (Beijing, China). The animals were housed under specific pathogen-free conditions and fed with chow and sterile water ad libitum in a 12 h light/dark cycle at 23 ± 2˚C. In total, 2x10 6 MG63 cells stably overexpressing miR-506 mimic or miR-control were subcutaneously injected into 4 to 6-week-old nude mice (n=8 per group). Tumors were measured with calipers to estimate the tumor volume between day 7 and 28 following injection according to the following formula: Tumor volume = 0.5 x length x width 2 . The mice were sacrificed a total of 28 days subsequent to inoculation, and tumour weights were measured. All animal procedures were performed with the approval of the Local Medical Experimental Animal Care Commission of the First Affiliated Hospital of Zhengzhou University.
Statistical analysis. All data are presented as the mean ± standard deviation, and analyzed using SPSS version 19.0 software (IBM SPSS, Armonk, NY, USA). The significance of the observed differences between groups was calculated using Student's t-test or one-way analysis of variance. P<0.05 was considered to indicate a statistically significant difference.
Results

Level of miR-506 is inversely associated with AEG-1 protein expression in osteosarcoma.
AEG-1 is ubiquitously expressed in numerous cell types and is overexpressed in certain solid tumors (25) . To determine whether AEG-1 is overexpressed in osteosarcoma, the expression level of AEG-1 in human osteosarcoma tissues and osteosarcoma MG63 cell line was measured using western blot analysis. As shown in 
Upregulation of miR-506 inhibits apoptosis of osteosarcoma cells.
The present study additionally assessed the effects of miR-506 and AEG-1 on the apoptosis of MG63 cells. Overexpression of miR-506 significantly increased the apoptotic rate of MG63 cells compared to the miR-control-transfected group (P=0.0265; Fig. 3A) . Similarly, downregulation of AEG-1 induced a higher apoptotic rate of MG63 cells compared with the si-control group (P=0.0137; Fig. 3B ). Overall, these results indicate that overexpression of miR-506 and downregulation of AEG-1 have a clear ability to induce MG63 cell apoptosis.
AEG-1 is directly targeted by miR-506 in MG63 cells.
Bioinformatics analysis using TargetScan suggested that miR-506 was a predicted to target AEG-1, and the 'seed sequence' of miR-506 matched the 3'-UTR of the AEG-1 mRNA (Fig. 4A) . To confirm AEG-1 was directly targeted and regulated by miR-506 in MG63 cells, luciferase reporter genes were constructed using the AEG-1 3'-UTR and the mutant counterpart at the miR-506 binding regions, and these were co-transfected with miR-506 mimics or miR-control into MG63 cells. Overexpression 
miR-506 inhibits osteosarcoma cell growth in vivo.
To investigate whether miR-506 has a role in a mouse model of osteosarcoma, MG63 cells stably overexpressing miR-506 or control-miR were injected subcutaneously into nude mice. The tumor volume was measured every 7 days. A total of 28 days following inoculation, mice were sacrificed and tumor weights were measured. Overexpression of miR-506 significantly inhibited the tumor growth of MG63 xenografts compared with the negative control group, since the average volume and weight of the miR-506-overexpressing tumors were notably decreased (P=0.0023 and P=0.0017, respectively; Fig. 5A and B) . Therefore, miR-506 clearly attenuates osteosarcoma cell growth in vivo.
miR-506 inhibits osteosarcoma development via regulation of the Wnt/β-catenin signaling pathway. The Wnt/β-catenin signaling pathway has been widely implicated in the development of multiple tumors, including osteosarcoma (26) . The present study detected the expression levels of β-catenin, c-myc, and cyclin D1 in MG63 cells to determine whether miR-506 inhibits osteosarcoma via the Wnt/β-catenin pathway. As shown in Fig. 6A , upregulation of miR-506 and downregulation of AEG-1 clearly decreased the expression A B levels of β-catenin (P=0.0268 and P=0.0134, respectively), c-myc (P=0.0166 and 0.0129, respectively) and cyclin D1 (P=0.0288 and P=0.0260, respectively) in MG63 cells. In addition, the Wnt/β-catenin signaling pathway was inhibited by the present study using si-β-catenin. The levels of β-catenin mRNA and protein were significantly decreased in MG63 cells following transfection (P=0.0011 and P=0.0103, respectively; Fig. 6B and C) . Blocking of the Wnt/β-catenin signaling pathway suppressed proliferation (P=0.0236) and induced apoptosis (P=0.0046) of MG63 cells (Fig. 6D and E) . Furthermore, CGP049090, a small molecule inhibitor of Wnt/β-catenin, inhibited the expression of β-catenin (5 µM, P=0.0227; 10 µM, P=0.0086), c-myc (5 µM, P=0.0213; 10 µM, P=0.0017) and cyclin D1 (5 µM, P=0.0243; 10 µM, P=0.0033) in MG63 cells in a concentration-dependent manner (Fig. 6F) . CGP049090 clearly inhibited proliferation (5 µM, P=0.0373; 10 µM, P=0.0088) and induced apoptosis (P=0.0008) of MG63 cells (Fig. 6G and H ). These data demonstrate that miR-506 suppresses osteosarcoma by regulation of AEG-1 through inhibition of the Wnt/β-catenin signaling pathway.
Discussion
To improve osteosarcoma therapy, novel therapeutic targets require identification, and therapeutic strategies need to be developed. Recently, the utilization of miRs has provided novel insights into osteosarcoma therapy. Numerous studies have revealed that miRs are critical as tumor suppressors or oncogenes in osteosarcoma. However, their involvements in the underlying molecular mechanisms remain to be further elucidated. The present study revealed that the expression level of miR-506 was decreased in osteosarcoma tissues and cells compared with matched adjacent non-cancerous bone tissues and normal osteoblastic cells, respectively. In addition, an overexpression of miR-506 was revealed to suppress osteosarcoma cell proliferation and enhance apoptosis in vitro, and inhibit The present data suggest that miR-506 is associated with the development and progression of osteosarcoma, and may be a promising diagnostic biomarker and therapeutic target for osteosarcoma. Recently, a study revealed that the miR-29 family are important in the development and progression of human osteosarcoma; serum levels of miR-29a and miR-29b were independent prognostic factors for overall and disease-free survival (9) . Other studies have revealed that detection of serum miR-133b, miR-206, miR-148a, miR-196a and miR-196b expression has clinical potential as novel diagnostic biomarkers and are efficient predictors of prognosis in osteosarcoma patients (27, 28) . Nevertheless, the carcinogenic mechanisms of these miRs on osteosarcoma have not been fully elucidate. Therefore, the present findings provide valuable information and therapeutic benefits in osteosarcoma development. AEG-1 is known to be involved in multiple human cancers (18) . Elevated AEG-1 expression is linked to progression of cervical intraepithelial neoplasia and poor prognosis in cervical cancer (29) . Knockdown of AEG-1 induced prostate cancer cell apoptosis via the activation of forkhead box 3a (30) . In the present study, to investigate whether the loss function of AEG-1 is connected to the development of osteosarcoma, the expression of AEG-1 was downregulated in MG63 cells. The results indicated that knockdown of AEG-1 inhibited cell proliferation, suppressed colony-forming ability and induced apoptosis. In summary, the present data demonstrates that AEG-1 is involved in mediating cell proliferation and survival. Similarly, a previous study has revealed that AEG-1 regulates the migration and invasion of osteosarcoma U2OS cells (22) . Furthermore, the present study confirmed that the 3'-UTR of AEG-1 is a functional target site for miR-506 in MG63 cells. Studies in other types of cancer have indicated that miR-506 has an antineoplastic function (14, 31) ; however, the role of miR-506 in tumor cells is not fully understood. A previous study indicated that downregulation of miR-506 in ovarian carcinoma facilitated an aggressive phenotype, whereas overexpression of miR-506 in ovarian cancer cells inhibited cell (32) . miR-506 also represents a novel class of miR that regulates E-cadherin and vimentin/N-cadherin in the suppression of epithelial-to-mesenchymal transition and metastasis, and is associated with a good prognosis in epithelial ovarian cancer (31) . To the best of our knowledge, the current results present the first evidence that miR-506 may have therapeutic potential against osteosarcoma.
The canonical Wnt/β-catenin signaling pathway is one of the fundamental mechanisms that regulates cell proliferation, polarity and cell fate determination during embryonic development and homeostatic self-renewal in multiple adult tissues (33) . Therefore, mutations in this pathway are often associated with cancer and other diseases. The Wnt/β-catenin signaling pathway has been revealed to be excessively activated in osteosarcoma and contributes to the development and progression of osteosarcoma (34, 35) . Dihydroartemisinin inhibits tumor growth of human osteosarcoma cells by elevating the catalytic activity of glycogen synthase kinase 3β (GSK3β), which results in lower protein level and transcriptional activity of β-catenin (36) . Overexpression of bone morphogenetic protein 9 decreased the expression levels of β-catenin mRNA and protein, downregulated its downstream proteins c-myc and osteoprotegerin, and suppressed the phosphorylation level of GSK-3β (Ser 9) in osteosarcoma cells (37) . In addition, a previous study revealed that celecoxib, a cyclooxygenase (COX)-2 inhibitor, exerted an inhibitory effect on the viability of MG63 cells in a time-and dose-dependent manner, by inhibiting the expression of β-catenin and c-myc, and encoding cyclin D1 (38) . This suggests that β-catenin is required for MG63 cell survival and the Wnt/β-catenin pathway is a COX-2-independent target for non-steroidal anti-inflammatory drugs in osteosarcoma. The present study revealed that the Wnt/β-catenin signaling pathway was suppressed by overexpression of miR-506 or downregulation of AEG-1. Additionally, inhibition of the Wnt/β-catenin signaling pathway by si-β-catenin or CGP049090 significantly attenuated the viability and evoked apoptosis of MG63 cells in the present study. Therefore, the present study suggests that AEG-1 promotes osteosarcoma development by activating the Wnt/β-catenin pathway, and miR-506 downregulates the expression of AEG-1, which inhibits the Wnt/β-catenin pathway and provides therapeutic benefits in osteosarcoma.
To conclude, the present study has demonstrated that overexpression of miR-506 suppresses proliferation and induces apoptosis of osteosarcoma cells by targeting AEG-1. In addition, the present study revealed that miR-506 exhibits antineoplastic abilities by regulating the Wnt/β-catenin pathway. These findings provide novel insights for miRs in osteosarcoma.
